Pharmaceutical Industry St. Louis | Clinical Program Planning

314-220-7067

camden@camdengroup.com

Menu

About Us
Our Services
Experience

Smart Advice. Exacting standards.
Meticulous Execution.

Exceptional Results.

The Camden Group, LLC provides clinical consulting, development, and implementation services to clients in the pharmaceutical industry, advancing product candidates from bench to IND and NDA/BLA. We work flexibly with each of our clients, tailoring the breadth and depth of our services to the development needs of each client.

Each of Our Clients Benefits From

Column

A Thorough Understanding of the Clinical, Regulatory, and Market Environments
A Focus on Concrete and Submission-Ready Deliverables

Column

Experience With and Access to FDA
Agility in Managing the Myriad Details Associated With Clinical Program Planning and Execution, Affording Each Client Peace of Mind and Assurance of the Highest Quality Results

At every step, we work closely with each of our clients to fully understand the client's objectives and ensure all needs are met. We invite you to explore our website and contact us to see how we can help your organization achieve your clinical research objectives.

About The Camden Group, LLC

Founded in 1999, The Camden Group, LLC provides a broad range of clinical development services to clients in the pharmaceutical industry. The Camden Group, LLC is uniquely qualified to help our clients advance product candidates from bench to IND and NDA/BLA. Each of The Camden Group, LLC principals transitioned into clinical research from successful careers in academic medicine and basic research, and worked on “blockbuster” drug development programs in large pharmaceutical companies prior to founding The Camden Group, LLC. Our extensive experience and success in both basic and clinical research, proven track record in advancing drug candidates from intriguing laboratory finding to pre-clinical readiness, IND filing, and through clinical development give us the unique ability to “see the whole picture” and guide our clients through the entire clinical development process, foreseeing and avoiding potential pitfalls and expediting the development process.

Our thorough understanding of the clinical, regulatory, and market environments, focus on concrete and submission-ready deliverables, experience with and access to FDA, and ability to interleave the myriad details associated with clinical program planning and execution afford our clients peace of mind and assure them of the highest quality results.

Our Principals

Click to edit

Column

Benjamin D. Schwartz, M.D., Ph.D.

Dr. Benjamin D. Schwartz earned his BA degree summa cum laude from Columbia College and his M.D. degree and Ph.D. degree in Immunology from the Albert Einstein College of Medicine in New York. He completed his residency and internship at Bronx Municipal Hospital Center. He then spent two years
as a Research Associate in the Laboratory of Immunology at the National Institutes of Allergy and
Infectious Diseases of the NIH, and subsequently joined the faculty of the Department of Medicine at Washington University School of Medicine in St.
Louis, Missouri, where he was also an Investigator of the Howard Hughes Medical Institute, and Chief of Rheumatology at Jewish Hospital. In 1991, he became Director of Immunology at Monsanto Corporate Research and oversaw a variety of basic research programs to identify drug candidates to treat autoimmune diseases. Dr. Schwartz joined Monsanto’s GD Searle Unit as Senior Director within the Arthritis Franchise and designed and directed
several of the clinical trials which contributed to the approval of Celebrex®. He then directed the clinical development program for Bextra®. In 1999, he co-founded The Camden Group, LLC. Dr. Schwartz is also a Rheumatologist and Professor of Clinical Medicine at Washington University School of Medicine, and
Attending Physician at Barnes-Jewish Hospital in St. Louis. He is Board Certified in Rheumatology, Internal Medicine, and Allergy and Immunology. He has been selected as one of the Best Doctors in America for 2005 -2018. He has served as the Chairman of the Research Council of the American College of
Rheumatology (ACR), as Chairman of the NIH Allergy and Immunology Study Section, and as a member of the Board of Directors of the ACR. Dr. Schwartz also serves on the Scientific Advisory Board of the Lupus Research Alliance. He is the author of over 150 original research articles, review articles, and chapters in text books, and holds 3 patents as the result of work performed for Camden Group, LLC clients.

Column

Laurel J. Mengle-Gaw, Ph.D.

Dr. Laurel J. Mengle-Gaw earned her BA degree in Chemistry and Biology with Highest Honors from the University of California, and her Ph.D. degree in Cancer Biology from Stanford University School of Medicine. Following postdoctoral research at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England, she began her career in the pharmaceutical industry at Monsanto Co. Corporate Research and G.D. Searle in St. Louis, Missouri, where she led basic research efforts to identify new drug candidates for disease targets in areas of strategic interest. Achievements included identification of new mechanistic targets, development of novel in vitro and in vivo model systems for candidate evaluation, and creation and direction of cross-functional research teams. In 1996, Dr. Mengle-Gaw joined G.D. Searle’s COX-2 inhibitor clinical research effort. In that capacity, she designed and managed multi-center Phase 2 and 3 clinical trials for Celebrex®, including the single largest pre-approval trial of Celebrex®, led the clinical team responsible for implementation of the 50-study clinical program for Bextra®, and designed Phase 1-3 clinical trials for the multiple indications for Bextra®. She was honored with awards for research excellence in both basic and clinical research from Monsanto Co. and G.D. Searle. She left G.D. Searle to co-found The Camden Group, LLC in 1999. Dr. Mengle-Gaw has authored over 40 original publications in peer-reviewed journals, invited reviews, and textbook chapters, spanning both basic and clinical science. She holds 3 patents as a result of work performed for Camden Group, LLC clients. She is a member of the American College of Rheumatology, American Pain Society, American Association of Immunologists, and the International Association for the Study of Pain.

Click to edit

What We Do

The Camden Group provides the following clinical development services to clients from the pharmaceutical industry:

Click to edit

Column

Clinical Consulting Services
Clinical Development Services

Column

Clinical Program Implementation Services
On-Site Clinical Development Services

Click to edit

We work flexibly with each of our clients, and tailor the breadth and depth of our services to the development needs of each client. At every step, we work closely with each of our clients to fully understand the client's objectives and ensure all needs are met. Working either independently or seamlessly with each client’s available R&D staff, we expedite clinical development by anticipating development needs and promptly resolving issues as they arise with a measure of responsiveness unparalleled in the industry. We are committed to delivering smart and common sense advice and the highest quality results for each of our clients.